Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis

Seung Min Jung; Hyun Sook Kim; Hae Rim Kim; Na Young Kim; Jung Hwa Lee; Juryun Kim; Seung Ki Kwok; Kyung Su Park; Sung Hwan Park; Ho Youn Kim; Ji Hyeon Ju

doi:10.1016/j.intimp.2014.04.006

Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis

Seung Min Jung, Hyun Sook Kim, Hae Rim Kim, Na Young Kim, Jung Hwa Lee, Juryun Kim, Seung Ki Kwok, Kyung Su Park, Sung Hwan Park, Ho Youn Kim, Ji Hyeon Ju

Division of Rheumatology

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

The aim of this study was to investigate the prevalence of antidrug antibodies (ADAs) against tumour necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). ADAs were detected in 18 (9.8%) patients with RA and in 18 (10.2%) patients with AS of the 360 patients. Development of ADAs was significantly associated with treatment failure in RA patients (P = 0.003). When classified by drugs, the prevalence of immunogenicity in descending order was 17 (28.8%) patients treated with infliximab, 17 (10.4%) with adalimumab, and 2 (1.4%) with etanercept. After adjustment for disease and duration of anti-TNF therapy, the odds ratio as a reference of adalimumab-treated patients was 9.159 (95% confidence interval [CI] 2.005-41.845) for infliximab and 0.280 (95% CI 0.128-0.611) for etanercept. The immunogenicity of anti-TNF therapy was highest in the infliximab-treated group and significantly lower in the etanercept-treated group.

Original language	English
Pages (from-to)	20-25
Number of pages	6
Journal	International Immunopharmacology
Volume	21
Issue number	1
DOIs	https://doi.org/10.1016/j.intimp.2014.04.006
State	Published - Jul 2014

Bibliographical note

Funding Information:
This study was supported by a grant from the Korea Healthcare Technology R&D Project , Ministry of Health and Welfare, Republic of Korea ( HI10C2020 , A092258 ). The funding source had no involvement in the study design, collection, analysis and interpretation of data; in the writing of the article; and in the decision to submit the article for publication.

Keywords

Ankylosing spondylitis
Antidrug antibody
Immunogenicity
Rheumatoid arthritis
TNF inhibitor

Access to Document

10.1016/j.intimp.2014.04.006

Cite this

@article{dd9bf07082fc42078698cd733b456303,

title = "Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis",

abstract = "The aim of this study was to investigate the prevalence of antidrug antibodies (ADAs) against tumour necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). ADAs were detected in 18 (9.8%) patients with RA and in 18 (10.2%) patients with AS of the 360 patients. Development of ADAs was significantly associated with treatment failure in RA patients (P = 0.003). When classified by drugs, the prevalence of immunogenicity in descending order was 17 (28.8%) patients treated with infliximab, 17 (10.4%) with adalimumab, and 2 (1.4%) with etanercept. After adjustment for disease and duration of anti-TNF therapy, the odds ratio as a reference of adalimumab-treated patients was 9.159 (95% confidence interval [CI] 2.005-41.845) for infliximab and 0.280 (95% CI 0.128-0.611) for etanercept. The immunogenicity of anti-TNF therapy was highest in the infliximab-treated group and significantly lower in the etanercept-treated group.",

keywords = "Ankylosing spondylitis, Antidrug antibody, Immunogenicity, Rheumatoid arthritis, TNF inhibitor",

author = "Jung, {Seung Min} and Kim, {Hyun Sook} and Kim, {Hae Rim} and Kim, {Na Young} and Lee, {Jung Hwa} and Juryun Kim and Kwok, {Seung Ki} and Park, {Kyung Su} and Park, {Sung Hwan} and Kim, {Ho Youn} and Ju, {Ji Hyeon}",

note = "Funding Information: This study was supported by a grant from the Korea Healthcare Technology R&D Project , Ministry of Health and Welfare, Republic of Korea ( HI10C2020 , A092258 ). The funding source had no involvement in the study design, collection, analysis and interpretation of data; in the writing of the article; and in the decision to submit the article for publication.",

year = "2014",

month = jul,

doi = "10.1016/j.intimp.2014.04.006",

language = "English",

volume = "21",

pages = "20--25",

journal = "International Immunopharmacology",

issn = "1567-5769",

publisher = "Elsevier B.V.",

number = "1",

}

TY - JOUR

T1 - Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis

AU - Jung, Seung Min

AU - Kim, Hyun Sook

AU - Kim, Hae Rim

AU - Kim, Na Young

AU - Lee, Jung Hwa

AU - Kim, Juryun

AU - Kwok, Seung Ki

AU - Park, Kyung Su

AU - Park, Sung Hwan

AU - Kim, Ho Youn

AU - Ju, Ji Hyeon

N1 - Funding Information: This study was supported by a grant from the Korea Healthcare Technology R&D Project , Ministry of Health and Welfare, Republic of Korea ( HI10C2020 , A092258 ). The funding source had no involvement in the study design, collection, analysis and interpretation of data; in the writing of the article; and in the decision to submit the article for publication.

PY - 2014/7

Y1 - 2014/7

N2 - The aim of this study was to investigate the prevalence of antidrug antibodies (ADAs) against tumour necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). ADAs were detected in 18 (9.8%) patients with RA and in 18 (10.2%) patients with AS of the 360 patients. Development of ADAs was significantly associated with treatment failure in RA patients (P = 0.003). When classified by drugs, the prevalence of immunogenicity in descending order was 17 (28.8%) patients treated with infliximab, 17 (10.4%) with adalimumab, and 2 (1.4%) with etanercept. After adjustment for disease and duration of anti-TNF therapy, the odds ratio as a reference of adalimumab-treated patients was 9.159 (95% confidence interval [CI] 2.005-41.845) for infliximab and 0.280 (95% CI 0.128-0.611) for etanercept. The immunogenicity of anti-TNF therapy was highest in the infliximab-treated group and significantly lower in the etanercept-treated group.

AB - The aim of this study was to investigate the prevalence of antidrug antibodies (ADAs) against tumour necrosis factor (TNF) inhibitors in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). ADAs were detected in 18 (9.8%) patients with RA and in 18 (10.2%) patients with AS of the 360 patients. Development of ADAs was significantly associated with treatment failure in RA patients (P = 0.003). When classified by drugs, the prevalence of immunogenicity in descending order was 17 (28.8%) patients treated with infliximab, 17 (10.4%) with adalimumab, and 2 (1.4%) with etanercept. After adjustment for disease and duration of anti-TNF therapy, the odds ratio as a reference of adalimumab-treated patients was 9.159 (95% confidence interval [CI] 2.005-41.845) for infliximab and 0.280 (95% CI 0.128-0.611) for etanercept. The immunogenicity of anti-TNF therapy was highest in the infliximab-treated group and significantly lower in the etanercept-treated group.

KW - Ankylosing spondylitis

KW - Antidrug antibody

KW - Immunogenicity

KW - Rheumatoid arthritis

KW - TNF inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84899638614&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2014.04.006

DO - 10.1016/j.intimp.2014.04.006

M3 - Article

C2 - 24752013

AN - SCOPUS:84899638614

SN - 1567-5769

VL - 21

SP - 20

EP - 25

JO - International Immunopharmacology

JF - International Immunopharmacology

IS - 1

ER -

Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this